Plausible Structural/Functional/Behavioral/Biochemical Transformations Following Myoblast Transfer Therapy

  • Peter K. Law
  • Tena G. Goodwin
  • H.-J. Li
  • Ming Chen
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 280)

Abstract

As of April 7, the Institutional Review Board has approved our proposal on human trial with myoblast transfer therapy.

Keywords

Fractionation Neurol Tetanus Penicillamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    J. Walton, “Disorders of Voluntary Muscle”, Churchill Livingstone, New York (1981) p. 487.Google Scholar
  2. 2.
    R.K. Roelof s, G.S. deArengo, P.K. Law, D. Kinsman and J.H. Park Treatment of Duchenne muscular dystrophy and D. LPenicillamine: Results of a double-blind trial. Arch. Neurol. 36: 266 (1979).CrossRefGoogle Scholar
  3. 3.
    McComas A.J., M.E. Brandstater, A.R.M. Upton, J. Delbeke, C. deFaria and K. Toyonaga. Sick motor neurons and dystrophy: A reappraisal, in “Pathogenesis of Human Muscular Dystrophies”. L.P. Rowland ed. Excerpta Medica, Amsterdam (1977) p. 180.Google Scholar
  4. 4.
    H. Meier, and J.L. Southard. Muscular dystrophy in the mouse caused by an allele at the dy-locus. Life Sci. 9: 137 (1970).PubMedCrossRefGoogle Scholar
  5. 5.
    P.K. Law. Reduced regenerative capability of dystrophic mouse muscle. Exp. Neurol. 60: 231 (1978).PubMedCrossRefGoogle Scholar
  6. 6.
    P.K. Law and J.L. Yap. New muscle transplant method produces normal twitch tension in dystrophic muscle. Muscle & Nerve 2: 356 (1979).CrossRefGoogle Scholar
  7. 7.
    P.K. Law. Beneficial effects of transplanting normal limb-bud mesenchyme into dystrophic mouse muscle. Muscle & Nerve 5: 619 (1982).Google Scholar
  8. 8.
    P.K. Law, T.G. Goodwin, and M.G. Wang. Normal myoblast injections provide genetic treatment for murine dystrophy. Muscle & Nerve 11: 525 (1988).CrossRefGoogle Scholar
  9. 9.
    P.K. Law. T.G. Goodwin, and H.J. Li. Histoincompatible myoblast injection improves muscle structure and function of dystrophic mice. Transplant Proc. 20: 1114 (1988).PubMedGoogle Scholar
  10. 10.
    P.K. Law, H-J. Li, T.G. Goodwin, G. Ajamoughli, X.Y. Zhang and M. Chen. Pathogenesis and treatment of hereditary muscular dystrophy. In press.Google Scholar
  11. 11.
    P.K. Law, and H.L. Atwood. Nonequivalence of surgical and natural denervation in dystrophic mouse muscles. Exp. Neurol. 34: 300 (1972).CrossRefGoogle Scholar
  12. 12.
    P.K. Law, H.L. Atwood, and A.J. McComas. Functional denervation in dystrophic mouse muscles. Exp. Neurol. 51: 434 (1976).PubMedCrossRefGoogle Scholar
  13. 13.
    P.K. Law. “Leaky” membrane causes weakness in dystrophic soleus fibers. Adv. Physiol. Sci. 5: 213 (1980).Google Scholar
  14. 14.
    B. Mokri and A.G. Engel. Duchenne dystrophy: electron microscopic findings pointing to a basic or early abnormality in the plasma membrane of the muscle fiber. Neurology 25: 1111 (1975).PubMedCrossRefGoogle Scholar
  15. 15.
    P.K. Law, A. Saito, and S. Fleischer. Ultrastructural changes in muscle and motor end-plate of the dystrophic mouse. Exp. Neurol. 80: 361 (1983).PubMedCrossRefGoogle Scholar
  16. 16.
    A. Saito, P.K. Law. and S. Fleischer. Study of neurotrophism with ultrastructure of normal/dystrophic parabiotic mice. Muscle & Nerve 6: 14 (1983).CrossRefGoogle Scholar
  17. 17.
    E.P. Hoffman, R.H. Brown, L.M. Kunkel, Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919 (1987).PubMedCrossRefGoogle Scholar
  18. 18.
    K.P. Campbell and S.D. Kahl. Association of dystrophin and an integral membrane glycoprotein. Nature 338: 259 (1989).PubMedCrossRefGoogle Scholar
  19. 19.
    G. Salviati et al. Cell fractionation studies indicate that dystrophin is a protein of surface membranes of skeletal muscle. Biochem. J. 258–837 (1989).Google Scholar
  20. 20.
    E. Cosmos and J. Butler. Differentiation of muscle transplanted between normal and dystrophic chickens in “Research in Muscle Development and the Muscle Spindle” B.Q. Banker et al. ed. Excerpta Medica. Amsterdam, (1972) p. 149.Google Scholar
  21. 21.
    L. Gransberg and E. Knutsson. Determination of dynamic muscle strength in man with acceleration controlled isokinetic movements. Acta Physiol. Scand. 119: 317 (1983).PubMedCrossRefGoogle Scholar
  22. 22.
    E. Knutsson, and A. Martensson. Isokinetic measurements of muscle strength in hysterical paresis. EEG Clin. Neurophysiol. 61: 370 (1985).CrossRefGoogle Scholar
  23. 23.
    E. Knutsson and A. Martensson. Posture and gait in parkinsonian patients. In “Disorders of Posture and Gait.” W. Bles and R.H. Brandt ed. Elsevier, Amsterdam, (1986) p. 217.Google Scholar
  24. 24.
    J. Isaacson, L. Gransberg and E. Knutsson. Three-dimensional electrogoniometric gait recording. J. Biomechanics 19: 627 (1986).CrossRefGoogle Scholar
  25. 25.
    T.A. Partridge, J.E. Morgan, G.R. Coulton, E.P. Hoffman and L.M. Kunkel. Conversion of mdx myofibres from dystrophinnegative to -positive by injection of normal myoblasts. Nature 33: 176 (1989).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Peter K. Law
    • 1
    • 2
  • Tena G. Goodwin
    • 1
    • 2
  • H.-J. Li
    • 1
    • 2
  • Ming Chen
    • 1
    • 2
  1. 1.Departments of Neurology and PhysiologyUniversity of TennesseeMemphisUSA
  2. 2.Departments of BiophysicsUniversity of TennesseeMemphisUSA

Personalised recommendations